Incyte's Minjuvi PBS listing in Australia adds a reimbursed, chemotherapy-free follicular lymphoma option, incrementally strengthening the non-Jakafi hematology portfolio.

What happened

Minjuvi (tafasitamab) plus rituximab and lenalidomide has been listed on Australia's PBS as the first chemotherapy-free CD19/CD20 dual-targeted immunotherapy for follicular lymphoma. This expands Incyte's commercial reach for Minjuvi, a brand the company has been scaling alongside Niktimvo, Zynyz, and povorcitinib to build a non-Jakafi revenue base. The listing comes at a time when Incyte's hematology/oncology portfolio grew 116% year-over-year in Q1 2026, though from a small base relative to Jakafi's $3.1B annual sales. While the PBS decision is a positive reimbursement milestone, the broader thesis still awaits proof that Opzelura demand and EU atopic dermatitis launch can accelerate enough to offset the 2028 Jakafi exclusivity cliff. The overall investment case remains in a 'Wait' posture, with the next 6–12 months critical for confirming that non-Jakafi growth is durable and demand-led rather than accounting-driven.

Implication

The PBS listing for Minjuvi in Australia provides a modest tailwind to Incyte's efforts to build a diversified hematology/oncology franchise. However, Minjuvi is a relatively small product—Q1 2026 hematology/oncology total was $ not specified but part of the $800M-$880M guidance—so the impact on overall revenue is incremental. Investors should watch for similar reimbursement wins in other markets that could accelerate the non-Jakafi portfolio's contribution, but the key catalyst remains Opzelura's performance. Without stronger evidence that Opzelura demand is accelerating and EU AD launch is on track, the stock's valuation already discounts much of the recent good news. Maintain the wait-and-see approach, favoring entry around $105, as the risk/reward is balanced at current levels.

Thesis delta

The PBS listing reinforces the non-Jakafi diversification narrative but does not change the core thesis, which hinges on Opzelura demand growth and EU launch execution. The news is incrementally positive, yet insufficient to upgrade the Wait rating, as the portfolio remains heavily dependent on Jakafi until larger growth drivers demonstrate scale.